SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ian@SI who wrote (1006)10/3/2000 12:20:13 PM
From: BostonView  Read Replies (2) of 1321
 
Visudyne Supplemental Filing Submitted to European
Union Health Authorities By QLT and CIBA Vision

New Application Submitted to EMEA for Eye Conditions Beyond Age-Related Macular Degeneration

ATLANTA, and VANCOUVER, British Columbia, Oct. 3 /PRNewswire/ -- CIBA Vision Corporation, the eye care unit of Novartis AG (NYSE: NVS - news), and QLT Inc. (Nasdaq: QLTI; Toronto) today announced the filing of an application for Visudyne(TM) (verteporfin) therapy with the European Medicines Evaluation Agency (EMEA) for the treatment of eye diseases other than age-related macular degeneration (AMD), the leading cause of blindness among people over the age of 50.

The submission by QLT and CIBA Vision to the EMEA seeks to expand the initial indication to include patients with other
ocular conditions characterized by choroidal neovascularization (CNV). These other diseases include pathologic myopia (PM), ocular histoplasmosis syndrome (OHS), angioid streaks, CNV due to certain retinal abnormalities, and idiopathic causes, among others. A similar supplemental new drug application (sNDA) filed recently to expand the indications was given priority
review status by the United States Food and Drug Administration (FDA).

biz.yahoo.com

BV
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News